# OUTRUN (NCT03497767)

> A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

No report yet. It can be ordered.

- Drugs tested: osimertinib plus stereotactic radiosurgery; osimertinib
- Indication: EGFR-mutated NSCLC with brain metastases

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03497767
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Trans Tasman Radiation Oncology Group
- Conditions: Metastatic Non Small Cell Lung Cancer
- Interventions: Osimertinib; Stereotactic Radiosurgery (SRS)
- Enrollment: 40
- Primary outcome: Intracranial progression free survival at 12 months

## Indexed commentary on OUTRUN so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 7
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=outrun-nct03497767

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03497767", "email": "<work email>"}; the inbox owner confirms by the emailed link.